Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 7:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 220 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: rosuvastatin calcium Clear all
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Focusing on the Menopausal Transition to Improve Mid-Life Women's Health

NCT06975111
View directory record Official record
Conditions
Menopause, Menopause Hot Flashes, Menopause Related Conditions, Cardiovascular
Interventions
Metformin, semaglutide, Anti-hypertensives, Lipid Lowering Medication, Life style intervention, Fezolinetant, Hormonal therapy
Drug · Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
45 Years to 55 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
3
States / cities
Aurora, Colorado • Chapel Hill, North Carolina • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 8, 2026, 7:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of MBX 1416 in Healthy Subjects

NCT06036784
View directory record Official record
Conditions
Postbariatric Hypoglycemia
Interventions
MBX 1416 (Part A), MBX 1416 (Part B), Placebo, MBX 1416 (Part C)
Drug
Lead sponsor
MBX Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Oct 8, 2026, 7:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study Between EDP-235, Midazolam, Caffeine and Rosuvastatin in Healthy Subjects

NCT05594615
View directory record Official record
Conditions
COVID-19
Interventions
EDP-235, Midazolam, Rosuvastatin, Caffeine
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Oct 8, 2026, 7:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From 5/45 mg Strength of ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) 45 mg and Rosuvastatin Calcium 5 mg

NCT00826358
View directory record Official record
Conditions
Healthy
Interventions
ABT-143, ABT-335, rosuvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 28, 2012 · Synced Oct 8, 2026, 7:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants

NCT07349394
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VNZ/TEZ/D-IVA, Rosuvastatin
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 8, 2026, 7:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants

NCT06416800
View directory record Official record
Conditions
Healthy Participants
Interventions
Digoxin, Rosuvastatin, Metformin, Povorcitinib, Probenecid
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Oct 8, 2026, 7:32 AM EDT
Terminated Phase 3 Interventional Results available

JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events

NCT00239681
View directory record Official record
Conditions
Elevated High-sensitivity C-Reactive Protein (hsCRP)
Interventions
Rosuvastatin, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
50 Years and older
Enrollment
17,802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
431
States / cities
Birmingham, Alabama • Calera, Alabama • Columbiana, Alabama + 428 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2014 · Synced Oct 8, 2026, 7:32 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Drug-Drug Interaction Study to Estimate the Effect of PF-07081532 on the Pharmacokinetics of Dabigatran and Rosuvastatin in Overweight or Obese Adult Participants

NCT05788328
View directory record Official record
Conditions
Healthy
Interventions
Dabigatran etexilate (DE), Rosuvastatin, PF-07081532
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 8, 2026, 7:32 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

The DEtermining Statin Intolerance FOr Rosuvastatin (DESIFOR) Trial

NCT03889314
View directory record Official record
Conditions
Cardiovascular Risk Factor, Cardiovascular Diseases, Adverse Effect
Interventions
Rosuvastatin 20mg, Placebo
Drug · Other
Lead sponsor
Minneapolis Heart Institute Foundation
Other
Eligibility
21 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Oct 8, 2026, 7:32 AM EDT
Completed Phase 3 Interventional Results available

Colchicine/Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial

NCT04472611
View directory record Official record
Conditions
SARS-CoV-2
Interventions
Standard of Care (SOC) and Colchicine+Rosuvastatin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
Bridgeport, Connecticut • Greenwich, Connecticut • New Haven, Connecticut + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Oct 8, 2026, 7:32 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial to Evaluate the Effects of MK-4646 on Rosuvastatin in Healthy Participants (MK-4646-007)

NCT07785830
View directory record Official record
Conditions
Healthy
Interventions
Rosuvastatin, MK-4646
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 8, 2026, 7:32 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.

NCT00300430
View directory record Official record
Conditions
Dyslipidemia, Coronary Heart Disease, Mixed Dyslipidemia
Interventions
ABT-335 and rosuvastatin calcium, ABT-335 and atorvastatin calcium, ABT-335 and simvastatin
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
1,911 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 23, 2009 · Synced Oct 8, 2026, 7:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Rosuvastatin and Atorvastatin in Pediatric Dyslipidemia Patients

NCT02364258
View directory record Official record
Conditions
Dyslipidemia
Interventions
Rosuvastatin, Atorvastatin
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
8 Years to 21 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Oct 8, 2026, 7:32 AM EDT
Recruiting Phase 3 Interventional

A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia

NCT07619118
View directory record Official record
Conditions
Hypercholesterolaemia
Interventions
laroprovstat/rosuvastatin 1, laroprovstat/rosuvastatin 2, laroprovstat/rosuvastatin 3, laroprovstat/rosuvastatin 4, Placebo to match laroprovstat/rosuvastatin 1,2,3, Placebo to match laroprovstat/rosuvastatin 4, Rosuvastatin 1, Rosuvastatin 2, Rosuvastatin 3, Rosuvastatin 4, Placebo to match Rosuvastatin
Combination Product · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
26
States / cities
Sun City West, Arizona • Gardena, California • Lomita, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 8, 2026, 7:32 AM EDT
Completed Phase 4 Interventional Results available

A Study Comparing CoQ10 Levels While Taking 3 Different Statins

NCT01660191
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Pitavastin 4mg, Atorvastatin 20mg, Rosuvastatin 5mg
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 8, 2026, 7:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study Between EDP-305, Midazolam, Caffeine and Rosuvastatin in Healthy Volunteers.

NCT03187496
View directory record Official record
Conditions
NASH
Interventions
Midazolam, Caffeine, Rosuvastatin, EDP-305
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Oct 8, 2026, 7:32 AM EDT
Completed Phase 3 Interventional Results available

Usability Study of the Commercial Auto-injector Device and the New Auto-injector Device (SYDNEY) in Patients With High or Very High CV Risk With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy

NCT03415178
View directory record Official record
Conditions
Hypercholesterolaemia
Interventions
Alirocumab SAR236553, Current auto-injector device (AI), New auto-injector device (SYDNEY), Atorvastatin, Rosuvastatin
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
13
States / cities
Los Angeles, California • Jacksonville, Florida • Ponte Vedra, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Oct 8, 2026, 7:32 AM EDT
Terminated Phase 3 Interventional

Efficacy of Lapaquistat Acetate Alone or Combined With High-Dose Statin Therapy in Subjects With Hypercholesterolemia

NCT00249899
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Lapaquistat acetate and stable statin therapy, Stable statin therapy
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
649 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
13
States / cities
Santa Ana, California • Chicago, Illinois • Iowa City, Iowa + 10 more
Source: ClinicalTrials.gov public record
Updated May 24, 2012 · Synced Oct 8, 2026, 7:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Study of Calderasib (MK-1084) With Rosuvastatin and Metformin in Healthy People (MK-1084-016)

NCT07222098
View directory record Official record
Conditions
Healthy
Interventions
Rosuvastatin, Metformin, Calderasib
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
19 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 8, 2026, 7:32 AM EDT
Recruiting Phase 3 Interventional

PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis

NCT07232069
View directory record Official record
Conditions
Coronary Artery Disease Risk Factors Multiple, Coronary Artery Disease Progression, Prevention & Control, Premature Atherosclerosis
Interventions
Rosuvastatin 20 Mg Oral Tablet, Colchicine 0.5 MG Oral Tablet Once Daily, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
30 Years to 60 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
23
States / cities
Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 8, 2026, 7:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects

NCT05384262
View directory record Official record
Conditions
Dyslipidemia
Interventions
AZD0780, Placebo, Rosuvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
183 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 8, 2026, 7:32 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Assessing Goldenseal-drug Interactions Using a Probe Drug Cocktail Approach

NCT03772262
View directory record Official record
Conditions
Interaction Drug Food
Interventions
goldenseal, Metformin, Furosemide, Midazolam oral solution, Rosuvastatin Oral Tablet
Dietary Supplement · Drug
Lead sponsor
Washington State University
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Apr 28, 2023 · Synced Oct 8, 2026, 7:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Learn the Effect of Drug BAY1817080 on the Way the Body Absorbs, Distributes and Excretes Another Drug Rosuvastatin in Healthy Adult Participants

NCT04252300
View directory record Official record
Conditions
Drug Interactions
Interventions
Rosuvastatin, Rosuvastatin + BAY1817080
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Oct 8, 2026, 7:32 AM EDT
Completed Phase 3 Interventional Results available

12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe

NCT00525824
View directory record Official record
Conditions
Hypercholesterolemia, Coronary Heart Disease, Atherosclerosis
Interventions
Rosuvastatin (Crestor), Ezetimibe, Simvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Brentwood, Tennessee
Source: ClinicalTrials.gov public record
Updated May 13, 2011 · Synced Oct 8, 2026, 7:32 AM EDT